scholarly journals Brain cholesterol metabolism and Parkinson's disease

2019 ◽  
Vol 34 (3) ◽  
pp. 386-395 ◽  
Author(s):  
Xuemei Huang ◽  
Nicholas W. Sterling ◽  
Guangwei Du ◽  
Dongxiao Sun ◽  
Christina Stetter ◽  
...  
2017 ◽  
Vol 26 (19) ◽  
pp. 3823-3836 ◽  
Author(s):  
Siyuan Zhang ◽  
Samantha A. Glukhova ◽  
Kim A. Caldwell ◽  
Guy A. Caldwell

2020 ◽  
Vol 29 (4) ◽  
pp. 324-324
Author(s):  
Uram Jin ◽  
Soo Jin Park ◽  
Sang Myun Park

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Daniel Macías-García ◽  
María Teresa Periñán ◽  
Laura Muñoz-Delgado ◽  
María Valle Jimenez-Jaraba ◽  
Miguel Ángel Labrador-Espinosa ◽  
...  

AbstractBrain cholesterol metabolism has been described as altered in Parkinson’s disease (PD) patients. Serum lipid levels have been widely studied in PD with controversial results among different populations and age groups. The present study is aimed at determining if the serum lipid profile could be influenced by the genetic background of PD patients. We included 403 PD patients (342 sporadic PD patients, 30 GBA-associated PD patients, and 31 LRRK2-associated PD patients) and 654 healthy controls (HCs). Total cholesterol, HDL, LDL, and triglycerides were measured in peripheral blood. Analysis of covariance adjusting for sex and age (ANCOVA) and post hoc tests were applied to determine the differences within lipid profiles among the groups. Multivariate ANCOVA revealed significant differences among the groups within cholesterol and LDL levels. GBA-associated PD patients had significantly lower levels of total cholesterol and LDL compared to LRRK2-associated PD patients and HCs. The different serum cholesterol levels in GBA-associated PD might be related to diverse pathogenic mechanisms. Our results support the hypothesis of lipid metabolism disruption as one of the main PD pathogenic mechanisms in patients with GBA-associated PD. Further studies would be necessary to explore their clinical implications.


2021 ◽  
Vol 16 (12) ◽  
pp. 196-208
Author(s):  
Nitu Dogra ◽  
Ruchi Jakhmola-Mani ◽  
Deepshikha Katare Pande

Parkinson’s disease (PD) is a chronic, progressive and second most prevalent neurological disorder affecting the motor system. It has been found that people suffering with inflammatory bowel disease (IBD) are 22% more prone to PD. In the current study, we have framed a hypothesis and deciphered protein-protein interaction network between the IBD and PD and therefore, have proposed a role of gut-brain axis in PD. Text mining for retrieval of Differentially Expressed protein (DEPs; specific to Homo sapiens) associated with PD and IBD was done using Science Direct, Pub Med Central, Sci ELO and JSTOR. The protein interaction network was constructed in Cytoscape (version 3.7.1) by using above 58 DEPs. The generated master network was further analyzed using BiNGO plugin for retrieval of overrepresented biological processes in IBD-PD pathologies. Hub nodes were also generated in the network. In the present study the gutbrain hypothesis was designed which demonstrates the series of protein interactions that ought to link IBD to PD. Major proteins involved in this connection were LRRK2, APOE, SNCA, IL6, HIF-1α, ABCA, TLR4, CREB1, IL10, ADORA2A, DRD2, INOS, CCL2, SLC6A3 and CASP3. These proteins could be used as druggable targets to halt the progression of PD pathogenesis initiating via IBD. The common biological pathways linking both the pathologies were found to be HIF-signaling, Cytokines interactions, JAK-STAT pathway, Cholesterol metabolism, cAMP mediated signaling and apoptosis. This study also suggests the role ABC transporters and APOE in linking IBD and PD via disturbance of cerebral homeostasis.


2021 ◽  
Vol 13 ◽  
Author(s):  
William J. Griffiths ◽  
Jonas Abdel-Khalik ◽  
Sarah F. Moore ◽  
Ruwani S. Wijeyekoon ◽  
Peter J. Crick ◽  
...  

Disordered cholesterol metabolism is linked to neurodegeneration. In this study we investigated the profile of cholesterol metabolites found in the cerebrospinal fluid (CSF) of Parkinson’s disease (PD) patients. When adjustments were made for confounding variables of age and sex, 7α,(25R)26-dihydroxycholesterol and a second oxysterol 7α,x,y-trihydroxycholest-4-en-3-one (7α,x,y-triHCO), whose exact structure is unknown, were found to be significantly elevated in PD CSF. The likely location of the additional hydroxy groups on the second oxysterol are on the sterol side-chain. We found that CSF 7α-hydroxycholesterol levels correlated positively with depression in PD patients, while two presumptively identified cholestenoic acids correlated negatively with depression.


2019 ◽  
Vol 17 (3) ◽  
pp. 295-306 ◽  
Author(s):  
Iván Carrera ◽  
Ramón Cacabelos

The research progress of understanding the etiology and pathogenesis of Parkinson's disease (PD) has yet lead to the development of some clinical approaches intended to treat cognitive and behavioral symptoms, such as memory and perception disorders. Despite the major advances in different genetic causes and risk factors for PD, which share common pathways to cell dysfunction and death, there is not yet a complete model of PD that can be used to accurately predict the effect of drugs on disease progression. Clinical trials are also important to test any novel neuro-protective agent, and recently there have been great advances in the use of anti-inflammatory drugs and plant flavonoid antioxidants to protect against specific neuronal degeneration and its interference with lipid and cholesterol metabolism. The increasing knowledge of the molecular events underlying the degenerative process of PD has stimulated research to identify natural compounds capable of halting or slowing the progress of neural deterioration. Polyphenols and flavonoids, which play a neuroprotective role in a wide array of in vitro and in vivo models of neurological disorders, emerged from among the multi-target bio-agents found mainly in plants and microorganisms. This review presents a detailed overview of the multimodal activities of neuroprotective bio-agents tested so far, emphasizing their neurorescue/neuroregenerative activity. The brain-penetrating property of bioagents may make these compounds an important class of natural drugs for the treatment of neurodegenerative diseases. Although there are numerous studies demonstrating beneficial effects in the laboratory by identifying critical molecular targets, the clinical efficacy of these neuroprotective treatments remains to be proven accurately.


Author(s):  
Nuriye Yıldırım Gökay ◽  
Bülent Gündüz ◽  
Fatih Söke ◽  
Recep Karamert

Purpose The effects of neurological diseases on the auditory system have been a notable issue for investigators because the auditory pathway is closely associated with neural systems. The purposes of this study are to evaluate the efferent auditory system function and hearing quality in Parkinson's disease (PD) and to compare the findings with age-matched individuals without PD to present a perspective on aging. Method The study included 35 individuals with PD (mean age of 48.50 ± 8.00 years) and 35 normal-hearing peers (mean age of 49 ± 10 years). The following tests were administered for all participants: the first section of the Speech, Spatial and Qualities of Hearing Scale; pure-tone audiometry, speech audiometry, tympanometry, and acoustic reflexes; and distortion product otoacoustic emissions (DPOAEs) and contralateral suppression of DPOAEs. SPSS Version 25 was used for statistical analyses, and values of p < .05 were considered statistically significant. Results There were no statistically significant differences in the pure-tone audiometry thresholds and DPOAE responses between the individuals with PD and their normal-hearing peers ( p = .732). However, statistically significant differences were found between the groups in suppression levels of DPOAEs and hearing quality ( p < .05). In addition, a statistically significant and positive correlation was found between the amount of suppression at some frequencies and the Speech, Spatial and Qualities of Hearing Scale scores. Conclusions This study indicates that medial olivocochlear efferent system function and the hearing quality of individuals with PD were affected adversely due to the results of PD pathophysiology on the hearing system. For optimal intervention and follow-up, tasks related to hearing quality in daily life can also be added to therapies for PD.


Sign in / Sign up

Export Citation Format

Share Document